Post-hoc phase III trial of Soliqua 100/33 (insulin glargine & lixisenatide injection) shows benefits in type 2 diabetes- Sanofi
Sanofi announced that Soliqua 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL lowered mean blood sugar levels (HbA1c) by between 1.09 and 2.41 percent after 30 weeks in adults with type 2 diabetes previously treated with between 15 and 40 units of basal insulin daily. This new post-hoc analysis of data from the LixiLan-L Phase 3 study, which grouped participants by HbA1c level at screening, also showed that all subgroups reached a mean HbA1c below 7 percent during the study period.
This post-hoc analysis reviewed data from the LixiLan-L pivotal Phase III trial, which compared the effectiveness of Soliqua 100/33 and insulin glargine 100 Units/mL in 736 adults whose type 2 diabetes was not adequately controlled at screening on between 15 and 40 units of basal insulin daily, alone or combined with one or two oral anti-diabetic agents. The primary outcome of the LixiLan-L study, a statistically significant reduction in HbA1c compared with insulin glargine 100 Units/mL, was previously reported.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins